Tag: shareholder

AB “Ignitis grupė” (hereinafter – the Group) informs that on the 1^st of August 2025 the Ministry of Finance of the Republic of Lithuania (hereinafter – the Ministry of Finance), which exercises the rights of the majority shareholder, announced the selection of three members from among civil servants to the Group’s Supervisory Board, in the areas of public policy and governance, regulatory, accounting and audit competences. Candidates may apply until the 21^st of August 2025 (inclusive).

AB “Ignitis grupė” (hereinafter – the Group) informs that on the 1^st of August 2025 the Ministry of Finance of the Republic of Lithuania (hereinafter – the Ministry of Finance), which exercises the rights of the majority shareholder, announced the selection of three members from among civil servants to the Group’s Supervisory Board, in the areas of public policy and governance, regulatory, accounting and audit competences. Candidates may apply until the 21^st of August 2025 (inclusive).

With over $4 billion in net assets, the Global X Uranium ETF is the world’s preeminent ETF providing investors broad exposure to companies involved in uranium mining and the production of nuclear components

This news release constitutes a "Designated News Release" incorporated by reference in the prospectus supplement dated December 9, 2024 to Fortis' short form base shelf prospectus dated December 9, 2024.

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline.

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Centene Corporation (NYSE: CNC) between December 12, 2024 and June 30, 2025, both dates inclusive (the “Class Period”), of the important September 8, 2025 lead plaintiff deadline.

Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 152,106 of the Company’s ordinary shares originally issued in January 2025 at a reduced exercise price of $11.57 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-282932) and an effective resale registration statement on Form S-1 (No. 333-284873). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $1.8 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.